Back to Search Start Over

Degradation of skeletal mass in locally advanced oesophageal cancer between initial diagnosis and recurrence

Authors :
Yacine Zouhry
Abdelkader Taibi
Sylvaine Durand-Fontanier
Tiffany Darbas
Geraud Forestier
Jacques Monteil
Valérie Lebrun-Ly
Philippe Fayemendy
Sophie Leobon
Pierre Jesus
Elise Deluche
CHU Limoges
Neuroépidémiologie Tropicale (NET)
Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST)
Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université de Limoges (UNILIM)
Malbec, Odile
Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-CHU Limoges-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST)
Université de Limoges (UNILIM)-Université de Limoges (UNILIM)
CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST)
Source :
BMC Cancer, BMC Cancer, BioMed Central, 2021, 21 (1), pp.1313. ⟨10.1186/s12885-021-09037-3⟩, BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

Background The prognostic value of a low skeletal mass index (SMI) has been investigated in locally advanced oesophageal (LAE) cancer at diagnosis. However, nothing is known about its evolution and clinical impact between initial diagnosis and recurrence. Methods A total of 89 patients treated for LAE cancer between January 2009 and December 2019 were included in this study. Computed tomography (CT) scans before treatment and at recurrence were evaluated. SMI and other body composition parameters were analysed by the L3 scan method. Results Participants were aged 66.0 (36.0–86) years. The incidence of low SMI increased by 12.3% between diagnosis and recurrence (70.7% vs. 83.0%, respectively) over a median follow-up of 16.9 (1.7–101.6) months. Patients with high SMI at diagnosis showed loss of muscle mass (58.0 vs. 55.2 cm2/m2, respectively; P 2, respectively; P = 0.05), but fat mass was increased (68.9 vs. 72.0 cm2/m2, respectively; P = 0.01). Patients with low SMI at diagnosis showed no significant changes in body composition parameters and no improvement of SMI, even with nutritional support. Low SMI (hazard ratio [HR]: 1.8; 95% confidence interval [CI]: 1.02–3.16) was an independent predictor (P = 0.041) of high nutritional risk index (HR: 1.79; 95% CI: 1.03–3.11; P = 0.039) at diagnosis. Conclusions The percentage of patients with a low SMI increased during follow-up. Our data suggest that an assessment of skeletal muscle parameters and nutrition support may be more useful in patients with a high SMI.

Details

Language :
English
ISSN :
14712407
Database :
OpenAIRE
Journal :
BMC Cancer, BMC Cancer, BioMed Central, 2021, 21 (1), pp.1313. ⟨10.1186/s12885-021-09037-3⟩, BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Accession number :
edsair.doi.dedup.....b522d96b43a335d56bbbf45fca379e76
Full Text :
https://doi.org/10.1186/s12885-021-09037-3⟩